Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)

Paysign, Inc. (NASDAQ:PAYS) reported Q2 2025 revenues up 33.12% year-over-year, primarily driven by a 189% surge in its Pharma segment due to US tariffs and new client acquisitions, despite a 4.7% decline in the core Plasma segment. While the company anticipates continued growth into 2026 within the patient affordability space, the stock is rated a Hold, trading at fair value around $5.83, as the Pharma segment's contribution has not yet offset the Plasma segment's overall impact or its recent weakness.

Analysis

Paysign, Inc. (PAYS) reported a robust 33.12% year-over-year revenue increase in its Q2 2025 results, signaling strong top-line performance. This growth is primarily attributable to its Pharma segment, which experienced an exceptional 189% YoY revenue surge driven by new client acquisitions and the impact of US tariffs. However, this impressive performance in the patient affordability space is partially offset by persistent weakness in the company's core Plasma segment, which saw a 4.7% YoY revenue decline due to ongoing headwinds from transitioning centers. While the company's guidance for H2 2025 and 2026 is optimistic, the analysis suggests a 'Hold' rating, as the stock's current price of approximately $5.83 is considered fair value. The key risk remains the underperformance of the Plasma segment, as the Pharma segment's revenue contribution, despite its rapid growth, does not yet fully compensate for the scale and recent decline of the Plasma business.

Key Decisions for Investors

• Given the stock is trading at a reported fair value of $5.83, current investors may consider holding their positions, while prospective investors should look for a more attractive entry point or confirmation of a turnaround in the core business.
• Investors must closely monitor the performance of the Plasma segment in subsequent quarters, as a stabilization or recovery from its 4.7% decline is the most critical factor for a potential re-rating of the stock.
• The sustainability of the Pharma segment's triple-digit growth is key to the investment thesis; therefore, tracking new client wins and the pace of expansion in the patient affordability space is essential to validate the company's optimistic outlook.